Malta - inglés - Medicines Authority

pharmascience international ltd lampousas 1, 1095 nicosia , cyprus - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 150 mg - antineoplastic agents

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ms pharma saudi (msps), saudi arabia - erlotinib - film-coated tablet - 25 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - erlotinib - film-coated tablet - 150 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sudair pharma company, saudi arabia - erlotinib - film-coated tablet - 100 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ms pharma saudi (msps), saudi arabia - erlotinib - film-coated tablet - 100 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ms pharma saudi (msps), saudi arabia - erlotinib - film-coated tablet - 150 mg

Malta - inglés - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 150 mg - antineoplastic agents

Israel - inglés - Ministry of Health

teva israel ltd - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib teva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib teva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib teva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib teva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israel - inglés - Ministry of Health

teva israel ltd - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib teva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib teva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib teva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib teva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Israel - inglés - Ministry of Health

teva israel ltd - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib teva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib teva is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib teva is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib teva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.